Treatment of moderate to severe asthma: Patient perspectives on combination inhaler therapy and implications for adherence

Journal of Asthma and Allergy

Volumn , Issue 2, 2009, Pages 63-72

  Murphy, Kevin R ^a   Bender, Bruce G ^b  

^a BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Adherence; Budesonide formoterol; Fluticasone salmeterol; Onset of effect; Patient satisfaction

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CICLESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; MOMETASONE FUROATE; MOMETASONE PLUS FORMOTEROL; MOMETASONE PLUS INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; STEROID; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FORCED EXPIRATORY VOLUME; HEALTH CARE PERSONNEL; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; METERED DOSE INHALER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 77953331476     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/jaa.s4214     Document Type: Review

References (65)

1. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med. 2002;166(8):1044-1049.
2. Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol. 2007;119(6):1454-1461. (Pubitemid 46863372)
3. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-844. (Pubitemid 39346477)
4. Bateman ED, Bousquet J, Busse WW, et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy. 2008;63(7):932-938.
5. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004;4(3):191-195. (Pubitemid 38685520)
6. Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy. 2009;64(5):784-789.
7. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114(6):1288-1293. (Pubitemid 39575880)
8. Marceau C, Lemière C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118(3):574-581. (Pubitemid 44301411)
9. Cabana MD, Rand CS, Becher OJ, Rubin HR. Reasons for pediatrician nonadherence to asthma guidelines. Arch Pediatr Adolesc Med. 2001;155(9):1057-1062.
10. Legorreta AP, Christian-Herman J, O'Connor RD, Hasan MM, Evans R, Leung KM. Compliance with national asthma management guidelines and specialty care: a health maintenance organization experience. Arch Intern Med. 1998;158(5):457-464. (Pubitemid 128681606)
11. Halm EA, Wisnivesky JP, Leventhal H. Quality and access to care among a cohort of inner-city adults with asthma: who gets guideline concordant care? Chest. 2005;128(4):1943-1950. (Pubitemid 41507525)
12. Wisnivesky JP, Lorenzo J, Lyn-Cook R, et al. Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol. 2008;101(3):264-270.
13. Baiardini I, Braido F, Giardini A, et al. Adherence to treatment: assessment of an unmet need in asthma. J Investig Allergol Clin Immunol. 2006;16(4):218-223. (Pubitemid 44198442)
14. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol. 2002;109(6 Suppl):S554-S559.
15. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005;25(1):107-130.
16. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130(1 Suppl):65S-72S. (Pubitemid 44107237)
17. Markson LE, Vollmer WM, Fitterman L, et al. Insight into patient dissatisfaction with asthma treatment. Arch Intern Med. 2001;161(3):379-384. (Pubitemid 32116553)
18. Ulrik CS, Backer V, Søes-Petersen U, Lange P, Harving H, Plaschke PP. The patient's perspective: adherence or non-adherence to asthma controller therapy? J Asthma. 2006;43(9):701-704. (Pubitemid 44722128)
19. Van Ganse E, Mörk AC, Osman LM, et al. Factors affecting adherence to asthma treatment: patient and physician perspectives. Prim Care Respir J. 2003;12(2):46-51. (Pubitemid 36841489)
20. Halm EA, Mora P, Leventhal H. No symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthma. Chest. 2006;129(3):573-580.
21. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. www.ginasthma.org. Updated December 2008. Accessed January 12, 2009.
22. National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. National Heart Lung and Blood Institute. www.nhlbi.nih.gov/guidelines/asthma/index.htm. Updated August 5, 2008. Accessed November 5, 2008.
23. Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007;29(5):823-843. (Pubitemid 47225183)
24. Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest. 2003;123(5):1480-1487.
25. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66(17):2235-2254. (Pubitemid 44878530)
26. Lyseng-Williamson KA, Simpson D. Budesonide/formoterol pressurized metered-dose inhaler. Drugs. 2008;68(13):1855-1864.
27. Aubier M, Pieters WR, Schlösser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999;93(12):876-884. (Pubitemid 30042638)
28. Bateman ED, Britton M, Carrillo J, Almeida J, Wixon C. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Investig. 1998;16(3):193-201. (Pubitemid 28477069)
29. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J. 1999;6(1):45-51.
30. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000;105(6 Pt 1):1108-1116. (Pubitemid 30418788)
31. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000;106(6):1088-1095. (Pubitemid 32006262)
32. Advair [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
33. Symbicort [package insert]. Wilmington, DE: AstraZeneca; 2009.
34. 2-agonists and corticosteroids. Eur Respir J. 2002;19(1):182-191.
35. Randomised, double-blind, parallel group study on the efficacy and tolerability of the salmeterol 50 mcg/fluticasone 250 mcg combination Diskus compared to the formoterol 6 mcg/budesonide 200 mcg combination Turbohaler administered twice daily in patients with moderate bronchial asthma. Study No. SAM40048 GlaxoSmithKline Clinical Study Register. http://gsk- clinicalstudyregister.com/files/pdf/997.pdf. Updated November 14, 2005. Accessed November 15, 2008.
36. Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin. 2004;20(2):225-240. (Pubitemid 38197324)
37. Busse WW, Shah SR, Somerville L, Parasuraman B, Martin P, Goldman M. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol. 2008;121(6):1407-1414.
38. Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med. 2006;100(7):1152- 1162. (Pubitemid 43809959)
39. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61(5):725-736. (Pubitemid 46587876)
40. Lasserson TJ, Cates CJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008(3):CD004106. (Pubitemid 351805468)
41. Ankerst J, Lötvall J, Cassidy S, Byrne N. Comparison of the bronchodilating effects of formoterol and albuterol delivered by hydrofluoroalkane pressurized metered-dose inhaler. Treat Respir Med. 2005;4(2):123-127. (Pubitemid 40613960)
42. Grembiale RD, Pelaia G, Naty S, Vatrella A, Tranfa CM, Marsico SA. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther. 2002;15(5):463-466. (Pubitemid 35333892)
43. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther. 2001;14(1):29-34. (Pubitemid 32158294)
44. van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther. 2004;17(2):89-95. (Pubitemid 38175340)
45. Hampel FC, Martin P, Mezzanotte WS. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. J Asthma. 2008;45(4):265-272. (Pubitemid 351630914)
46. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med. 2005;99(10):1263-1267.
47. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113(2):245-251. (Pubitemid 38210545)
48. Chervinsky P, Baker J, Bensch G, et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol. 2008;101(5):463-473.
49. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin. 2008;24(3):879-894.
50. Mathias SD, Warren EH, Colwell HH, Sung JC. A new treatment satisfaction measure for asthmatics: a validation study. Qual Life Res. 2000;9(7):873-882.
51. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76-83.
52. Hays RD, Stewart AL. Sleep measures: definitions and issues. In: Stewart AL, Ware JE, eds. Measuring Function and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1991:235-259.
53. Szeinbach SL, Murawski MM, McGhan WF, Corey R, Barnes JH. Using conjoint analysis to evaluate health state preferences. Drug Inf J. 1999;33(3):849-858. (Pubitemid 29399780)
54. Johansson G, Ställberg B, Tornling G, et al. Asthma treatment preference study: a conjoint analysis of preferred drug treatments. Chest. 2004;125(3):916-923. (Pubitemid 38367282)
55. Bender BG, Long A, Parasuraman B, Tran ZV. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol. 2007;98(4):322-328. (Pubitemid 46582122)
56. Leidy NK, Matthias SD, Parasuraman BM, Patrick DL, Pathak D. Development and validation of an onset of effect questionnaire for patients with asthma. Allergy Asthma Proc. 2008;29(6):590-599.
57. Kaiser H, Parasuraman B, Boggs R, Miller CJ, Leidy NK, O'Dowd L. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids. Ann Allergy Asthma Immunol. 2008;101(3):295-303.
58. Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O'Brien CD. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin. 2009;25(6):1563-1571.
59. Patrick DL, Martin ML, Bushnell DM, Meltzer EO, Parasuraman BM. Development of a treatment satisfaction measure for asthma patients: the asthma treatment satisfaction measure (ATSM) [ATS abstract 573]. Am J Respir Crit Care Med. 2008;177(abstract issue):A573.
60. O'Connor RD, Patrick DL, Parasuraman BM, Martin P, Goldman M. Patient satisfaction during treatment with adjustable-dose budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI), fixed-dose BUD/FM pMDI, and fixed-dose fluticasone/salmeterol dry powder inhaler (FP/SM DPI) [ATS abstract 609]. Am J Respir Crit Care Med. 2008;177(abstract issue):A609.
61. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129-136. (Pubitemid 40105411)
62. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20(9):1403-1418. (Pubitemid 39361344)
63. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368(9537):744-753. (Pubitemid 44279053)
64. 2-adrenoceptor agonist single-inhaler combination for both maintenance and rescue therapy: a paradigm shift in asthma management. Treat Respir Med. 2006;5(6):385-391.
65. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J. 2005;26(5):819-828. (Pubitemid 41632038)